ELCC 2016: CheckMate 171, phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer

ELCC 2016: CheckMate 171, phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer

User Photo
VJOncology

4 years
274 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, discusses CheckMate 171, a multicenter phase 2 trial of nivolumab, an anti-PD-1 monoclonal antibody, in patients with stage IIIB/IV squamous cell non-small cell lung cancer who have received at least one prior systemic treatment.
Up Next Autoplay